Synageva Biopharma Corp (GEVA) financial statements (2022 and earlier)

Company profile

Business Address 33 HAYDEN AVE.
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

Current Assets
Cash, cash equivalents, and short-term investments446,908408,733218,953
Cash and cash equivalents82,65362,13723,883
Short-term investments364,255346,596195,070
Prepaid expense1,238958
Prepaid expense and other current assets3,555
Other current assets3,601840
Other undisclosed current assets4,0814,819 
Total current assets:457,832416,723225,107
Noncurrent Assets
Property, plant and equipment31,55917,2134,012
Long-term investments and receivables2,000  
Long-term investments2,000  
Intangible assets, net (including goodwill)10,53812,02614,099
Intangible assets, net (excluding goodwill)2,0033,4915,564
Restricted cash and investments2,2741,987 
Other noncurrent assets4,2741,987
Prepaid expense and other noncurrent assets38
Other undisclosed noncurrent assets(4,274)(1,987) 
Total noncurrent assets:46,37131,22618,149
TOTAL ASSETS:504,203447,949243,256
Current Liabilities
Accounts payable and accrued liabilities30,42816,9329,550
Accounts payable2,6252,4272,576
Accrued liabilities21,71011,2615,112
Employee-related liabilities6,0933,2441,862
Deferred revenue and credits 2325,391
Other liabilities908  
Other undisclosed current liabilities(6,093)(3,244)(1,862)
Total current liabilities:25,24313,92013,079
Noncurrent Liabilities
Liabilities, other than long-term debt5,7213,828 
Other liabilities5,7213,828 
Total noncurrent liabilities:5,7213,828 
Total liabilities:30,96417,74813,079
Stockholders' equity
Stockholders' equity attributable to parent473,239430,201230,177
Common stock333124
Additional paid in capital920,333684,468388,936
Accumulated other comprehensive income (loss)(240)(59)6
Accumulated deficit(446,887)(254,239)(158,789)
Total stockholders' equity:473,239430,201230,177
TOTAL LIABILITIES AND EQUITY:504,203447,949243,256

Income statement (P&L) ($ in thousands)

Revenue, net6,49213,37415,054
Gross profit:6,49213,37414,954
Operating expenses(198,625)(109,277)(57,975)
Other operating expense, net
(Other Expenses)
Other undisclosed operating income600  
Operating loss:(192,133)(95,903)(43,021)
Nonoperating expense(4,036)(2,327)(310)
Investment income, nonoperating(3,798)(2,486)(310)
Loss from continuing operations before equity method investments, income taxes:(196,169)(98,230)(43,331)
Loss from equity method investments(616)  
Other undisclosed income from continuing operations before income taxes4,6772,828 
Loss from continuing operations before income taxes:(192,108)(95,402)(43,331)
Income tax expense(540)(48) 
Net loss:(192,648)(95,450)(43,331)
Other undisclosed net income attributable to parent  382
Net loss available to common stockholders, diluted:(192,648)(95,450)(42,949)

Comprehensive Income ($ in thousands)

Net loss:(192,648)(95,450)(43,331)
Comprehensive loss:(192,648)(95,450)(43,331)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(181)(65)392
Comprehensive loss, net of tax, attributable to parent:(192,829)(95,515)(42,939)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios


Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: